Validity evidence for an instrument for cognitive load for virtual didactic sessions

Background: COVID necessitated the shift to virtual resident instruction. The challenge of learning via virtual modalities has the potential to increase cognitive load. It is important for educators to reduce cognitive load to optimize learning, yet there are few available tools to measure cognitive load. The objective of this study is to identify and provide validity evidence following Messicks’ framework for an instrument to evaluate cognitive load in virtual emergency medicine didactic sessions.
Methods: This study followed Messicks’ framework for validity including content, response process, internal structure, and relationship to other variables. Content validity evidence included: (1) engagement of reference librarian and literature review of existing instruments; (2) engagement of experts in cognitive load, and relevant stakeholders to review the literature and choose an instrument appropriate to measure cognitive load in EM didactic presentations. Response process validity was gathered using the format and anchors of instruments with previous validity evidence and piloting amongst the author group. A lecture was provided by one faculty to four residency programs via ZoomTM. Afterwards, residents completed the cognitive load instrument. Descriptive statistics were collected; Cronbach’s alpha assessed internal consistency of the instrument; and correlation for relationship to other variables (quality of lecture).
Results: The 10-item Leppink Cognitive Load instrument was selected with attention to content and response process validity evidence. Internal structure of the instrument was good (Cronbach’s alpha = 0.80). Subscales performed well-intrinsic load (α = 0.96, excellent), extrinsic load (α = 0.89, good), and germane load (α = 0.97, excellent). Five of the items were correlated with overall quality of lecture (< 0.05).
Conclusions: The 10-item Cognitive Load instrument demonstrated good validity evidence to measure cognitive load and the subdomains of intrinsic, extraneous, and germane load. This instrument can be https://biodas.org/ used to provide feedback to presenters to improve the cognitive load of their presentations.

Assessment of the influence of gluten quality on highland barley dough sheet quality by different instruments

  • This study was to compare the results of texture analyzer with those of farinograph and extensograph and determine whether texture analyzer could be used to evaluate the processing quality of highland barley flour (HBF) dough sheet. The farinograph and extensograph tests were used to determine the reconstituted flour properties, a texture analyzer was applied to measure the tensile strength of HBF dough sheet, and the content of glutenin macropolymer (GMP), free sulfhydryl (-SH) and secondary structure of protein and microstructure in HBF dough sheet were investigated. Furthermore, correlations between these parameters were determined by regression analysis and Pearson correlation coefficient.
  • It was suggested that the reconstituted flours with a higher gluten index showed a higher farinograph quality number (FQN) and greater maximum resistance to extension (Rm ). HBF dough sheets with higher gluten index possessed higher GMP and lower free -SH contents, a more ordered secondary structure of protein, resulting in a more compact gluten network and a stronger tensile strength (TS).
  • The regression and correlation analysis showed that TS was positively correlated with FQN and Rm . In addition, it was significantly correlated with the content of GMP, -SH, secondary structure of protein and gluten network. It was concluded that texture analyzer could be an alternative approach to evaluate the processing quality of HBF dough sheet. Moreover, the gluten index of flours could be used to predict the processing quality of HBF dough sheet. This article is protected by copyright. All rights reserved.

Development of an Instrument to Assess the Stability of Cementless Femoral Implants Using Vibration Analysis During Total Hip Arthroplasty

Objective: The level of primary implant fixation in cementless total hip arthroplasty is a key factor for the longevity of the implant. Vibration-based methods show promise for providing quantitative information to help surgeons monitor implant fixation intraoperatively. A thorough understanding of what is driving these changes in vibrational behavior is important for further development and improvement of these methods. Additionally, an instrument must be designed to enable surgeons to leverage these methods. This study addresses both of these issues.
Method: An augmented system approach was used to develop an instrument that improves the sensitivity of the vibrational method and enables the implementation of the necessary excitation and measurement equipment. The augmented system approach took into account the dynamics of the existing bone-implant system and its interaction with the added instrument.
Results: Two instrument designs are proposed, accompanied by a convergence-based method to determine the insertion endpoint. The modal strain energy density distribution was shown to affect the vibrational sensitivity to contact changes in certain areas.
Conclusion: The augmented system approach led to an instrument design that improved the sensitivity to changes in the proximal region of the combined bone-implant-instrument system. This fact was confirmed both in silico and in vitro. Clinical Impact: The presented method and instruments address practical intraoperative challenges and provide perspective to objectively support the surgeon’s decision-making process, which will ensure optimal patient treatment.

Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above

Background: Patient activation comprises the skills, knowledge and motivation necessary for patients’ effective contribution to their care. We adapted and validated the 13-item Patient Activation Measure (PAM-13) in the ≥ 40 years old Hungarian general population.
Methods: A cross-sectional web survey was conducted among 900 respondents selected from an online panel via quota sampling. After 10 days, the survey was repeated on 100 respondents. The distribution, internal consistency, test-retest reliability, factor structure, convergent, discriminant and known-groups validity of PAM-13 were assessed according to the COSMIN guidelines.
Results: The sample comprised 779 respondents. Mean (± SD) age was 60.4 ± 10.6 years, 54% were female and 67% had chronic illness. Mean (± SD) PAM-13 score was 60.6 ± 10.0. We found good internal consistency (Cronbach alpha: 0.77), moderate test-retest reliability (ICC: 0.62; n = 75), a single-factor structure and good content validity: PAM-13 showed moderate correlation with the eHealth Literacy Scale (r = 0.40), and no correlation with age (r = 0.02), education (r = 0.04) or income (ρ = 0.04). Higher PAM-13 scores were associated with fewer lifestyle risks (p < 0.001), more frequent health information seeking (p < 0.001), participation in patient education (p = 0.018) and various online health-related behaviours. When controlling for health literacy, sociodemographic factors and health status, the association of higher PAM-13 scores with overall fewer lifestyle risks, normal body mass index, physical activity and adequate diet remained significant. Similar properties were observed in the subgroup of participants with chronic morbidity, but not in the age group 65+.
Conclusion: PAM-13 demonstrated good validity in the general population. Its properties in clinical populations and the elderly as well as responsiveness to interventions warrant further research.

TIP 300UL CONDUCTIVITY - TYPE QIAGEN AND DIAGNOSTIC INSTRUMENTS,NONSTERILE,96/2304

QT-300-CBK-R CORNING 2304/pk 282 EUR

20UL CLEAR TIPS FOR PACKARDS PLATE TRACK, EVOLUTION AND MINI TRACK INSTRUMENTS.

PK-20-R CORNING 960/pk 302.4 EUR

200UL CLEAR TIPS FOR PACKARDS PLATE TRACK, EVOLUTION AND MINI TRACK INSTRUMENTS.

PK-200-R CORNING 960/pk 342 EUR

50UL CLEAR TIPS FOR PACKARDS PLATE TRACK, EVOLUTION AND MINI TRACK INSTRUMENTS.

PK-50-R CORNING 960/pk 298.8 EUR

SmartBlock 24 x 1.5ml Thermoblock for ThermoMixer and ThermoStat instruments - EACH

E5360000038 Scientific Laboratory Supplies EACH 759.37 EUR

SmartBlock 24 x 0.5ml Thermoblock for ThermoMixer and ThermoStat instruments - EACH

E5361000031 Scientific Laboratory Supplies EACH 759.37 EUR

SmartBlock 24 x 2.0ml Thermoblock for ThermoMixer and ThermoStat instruments - EACH

E5362000035 Scientific Laboratory Supplies EACH 775.53 EUR

SmartBlock 4 x 50ml Thermoblock for ThermoMixer and ThermoStat instruments - EACH

E5365000028 Scientific Laboratory Supplies EACH 703.35 EUR

SmartBlock 8 x 15ml Thermoblock for ThermoMixer and ThermoStat instruments - EACH

E5366000021 Scientific Laboratory Supplies EACH 775.53 EUR

200UL CLEAR MAXYMUM RECOVERY TIPS FOR PACKARD"S PLATE TRACK, EVOLUTION AND MINI TRACK INSTRUMENTS

PK-200-L-R CORNING 960/pk 360 EUR

SmartBlock 12mm Thermoblock for 24 x 11-11.9mm dia tubes for ThermoMixer and ThermoStat instruments - EACH

E5364000024 Scientific Laboratory Supplies EACH 942.97 EUR

SmartBlock PCR 96 Thermoblock for 96 well PCR plates inc Lid for ThermoMixer and ThermoStat instruments - EACH

E5306000006 Scientific Laboratory Supplies EACH 942.97 EUR

SmartBlock PCR 384 Thermoblock for 384 well PCR plates inc Lid for ThermoMixer and ThermoStat instruments - EACH

E5307000000 Scientific Laboratory Supplies EACH 942.97 EUR

SmartBlock plates Thermoblock for MTP and Deepwell plates inc Lid for ThermoMixer and Thermo tat instruments - EACH

E5363000039 Scientific Laboratory Supplies EACH 942.97 EUR

SEPTA MAT, FOR 96 WELL PCR PLATES, SILICONE, GREY, NONSTERILE, FOR ABI MULTI-CAPILLARY SEQUENCING INSTRUMENTS, BULK

AM-96-SEPTA-3100 CORNING 10/pk 639.6 EUR

Add-on Instrument

C55 DataApex - 420 EUR

q-16 qPCR Instrument

Z-genesig-q16 Novacyt Group each 9375 EUR

q-32 qPCR Instrument

Z-genesig-q32 Novacyt Group each 18750 EUR

q-16 qPCR Instrument - RUO

R10016 Novacyt Group each 9375 EUR

q-32 qPCR Instrument - RUO

R10032 Novacyt Group each 18750 EUR

AnaPrep 12 Instrument

Z1321001 Biochain 1 unit 27916.8 EUR

MyGo Pro qPCR Instrument

R32-Z-MyGo-Pro Novacyt Group each 13750 EUR

Differential gene expression and chemical patterns of an intertidal crab inhabiting a polluted port and an adjacent marine protected area

The acquisition of data to safeguard marine protected areas located close to ports is important in order to develop plans that allow effective protection from pollution as well as sustainable development of the port. The area Secche della Meloria is a Marine Protected Area (MPA-MEL) three miles from Livorno Harbour (LH), which is characterized by a long history of pollution. Here we studied the bioaccumulation and transcriptomic patterns of the marbled crab, Pachygrapsus marmoratus (Fabricius, 1787) (Crustacea; Brachyura, Grapsidae), inhabiting the two selected sites.
Results showed that the two crab populations are significantly different in their chemical composition of trace elements and Polyciclic Aromatic Hydrocarbons (PAHs), and gene expression patterns (1280 DEGs). Enrichment analysis indicated that crabs at LH had the highest stress response genes, and they were associated with higher levels of bioaccumulation detected in body tissues. We are confident that the significant differential gene expression profiles observed between crabs, characterized by https://biodas.org/ significant chemical differences, is associated with responses to contaminant exposure.

Comparison of Perioperative Outcomes Between Single-Port and Multi-Port Robotic Adrenalectomy

Background: Single-port (SP) robotic surgery has been utilized in several surgical procedures. We aim to describe our institution’s approach and perioperative experience with SP robotic adrenalectomy and compare it to the traditional multi-port (MP) approach.
Methods: We retrospectively reviewed all patients who underwent robotic adrenalectomy by a single surgeon between March 2019 and March 2020. Patient demographic, perioperative factors, and pathologic outcomes were recorded and analyzed using t-tests, chi-square, or Fisher’s exact tests.
Results: Thirty-six patients underwent SP (n = 11) and MP (n = 25) robotic adrenalectomy. Age, body mass index, gender, operative time, major Clavien-Dindo complications, and margin status showed no differences. Patients undergoing SP adrenalectomy had a lower estimated blood loss (18.1 ± 13.0 vs 65.6 ± 95.0 cc, P = .02) and smaller lesion size (2.8 ± 1.3 vs 4.1 ± 1.8 cm, P = .04) compared to those undergoing MP.
Conclusions: SP adrenalectomy appears to be a feasible approach in select adrenal masses. Further studies are needed to establish its safety and cost effectiveness.

Analysis of ocular injury 1-year outcome in survivors of Beirut Port ammonium nitrate blast

Purpose: Ascertain the 1-year outcome of patients who sustained open eye injuries from the Beirut Port ammonium nitrate (AN) explosion, one of the most powerful non-nuclear explosions in history.
Methods: Retrospective chart review of the operated eyes in 2 major eye hospitals.
Results: Out of 42 patients with open globe injury that was originally sutured, 29 patients (34 eyes) were followed at the 1-year mark. The initial vision in logMAR (mean ± SD) was 2.93 ± 0.87 (hand motion equivalent) and the final vision was 1.80 ± 1.47 (counting finger 2 m equivalent). No light perception (NLP) vision was noted in 12 eyes on presentation and 10 eyes remained so, while 2 eyes reached light perception (LP) vision. Eight eyes had an intraoperative expulsive choroidal hemorrhage (7 NLP and 1 LP both pre- and postoperatively), and 6 of the 8 developed phthisis. All eyes that developed phthisis had NLP preoperatively and postoperatively. Ocular Trauma Score (OTS) correlated inversely with both initial and final vision (p < 0.001). Zone of injury inversely correlated with initial vision (p = 0.02) and positively with final vision (p < 0.001). Final vision was significantly worse in zone 3 vs. zones 1 and 2 (3.2 ± 0.5) vs. 0.9 ± 1.1) (p < 0.001) injuries, as was the initial vision (3.3 ± 0.5 vs. 2.7 ± 0.8; p = 0.002).
Conclusion: The OTS, which provides prognostic information for serious ocular trauma, also yields valuable prognostic information for AN-associated ocular injuries. Expulsive choroidal hemorrhage and NLP vision at presentation remain very poor prognostic signs.

Da Vinci SP Single-Port Robotic Surgery in Gynecologic Tumors: Single Surgeon’s Initial Experience with 100 Cases

Purpose: To report preliminary experience of single-port robotic surgery using the da Vinci SP surgical system in gynecologic tumors.
Materials and methods: This was a retrospective study on 100 consecutive patients who underwent da Vinci SP single-port robotic surgery between November 2018 and January 2021. All procedures were performed by an experienced gynecologic surgeon using a single 2.5-cm umbilical incision.
Results: Of the 100 cases, the procedures included myomectomy (n=76), hysterectomy (n=2), endometrial cancer surgical staging (n=14), radical hysterectomy (n=3), radical trachelectomy (n=3), and ovarian cystectomy (n=2). None of the cases was converted to robotic multiport or open surgery. The median docking time was 5.0 minutes [interquartile range (IQR), 3.0-7.0], the median console time was 107.5 minutes (IQR, 78.7-155.8), and the median total operation time was 250.0 minutes (IQR, 215.0-310.0). The median estimated blood loss was 50.0 mL (IQR, 30.0-100.0), and the median change in hemoglobin level was 0.8 g/dL (IQR, 0.3-1.3). The median pain scores rated on a numerical rating scale immediately after and at 6, 12, and 24 hours after surgery were 5, 2, 2, and 2, respectively. The mean duration of postoperative hospitalization was 2.8 days.
Conclusion: Da Vinci SP single-port robotic surgery was successfully performed in various gynecologic tumors without significant complications. Therefore, this surgical system could be applied in patients who want precise gynecologic surgery while minimizing surgical incision.

Anxiety, Depression and PTSD in Children and Adolescents following the Beirut Port Explosion

Background: On August 4, 2020, Beirut’s port experienced one of the strongest non-nuclear explosions in history, killing approximately 200 people, displacing 300,000 persons, and injuring more than 1000 children.
Methods: An online anonymous survey assessed the prevalence of probable mental health disorders (MHDs) and impact of blast-related and other factors controlling for sociodemographics in 801 children aged 8 to 17 years old.
Results: About two thirds (64%) were screened positive for probable anxiety using the Screen for Childhood Anxiety Related Disorder, 52% for probable PTSD using CRIES-13, and 33% for probable depression using the Mood and Feelings Questionnaire (MFQ). Children who resided farthest way from the explosion site or were not in Beirut during blast had a significantly lower odds of anxiety and PTSD. Children who sustained any physical injury (vs. none) or witnessed casualties (vs. not) were at higher odds for PTSD. Children of parents who reported that their homes sustained minor damages (vs. no damages at all) were at higher odds for anxiety and PTSD, and temporary displacement (vs. none) increased odds of PTSD only. Poorer perceived economic status, poorer academic performance, having a family member injured in the blast, and prior mental health care seeking were associated with higher odds for all MHDs.
Conclusion: Our study, the only one to document the mental health impact of the Beirut Port explosion on children, highlights the critical need for an emergency mental health response, prioritizing disadvantaged communities and children with prior mental health problems.

8-Port Manifolds

9621 Genesee Scientific 10 Manifolds/Unit 40.6 EUR

NBS 6 Port Gassing Manifold - EACH

SHA1124 Scientific Laboratory Supplies EACH 1074.6 EUR

Digitally controlled triple block heater with gas heater, no manifolds. 115V

109A11-09951 Glascol each 3274 EUR

Kinesis Manifold Body 6 Port 1/8in - EACH

CHR3821 Scientific Laboratory Supplies EACH 349.65 EUR

Kinesis Manifold Assy 6 Port 1/16in - EACH

CHR3817 Scientific Laboratory Supplies EACH 380.7 EUR

Kinesis Manifold Assembly 5 Port; 1/16; PEEK

CHR3825 Scientific Laboratory Supplies EACH 183.18 EUR

Kinesis Manifold Body 7 Port; 1/16; PEEK - EACH

CHR3813 Scientific Laboratory Supplies EACH 166.05 EUR

Kinesis Manifold Assembly 7 Port; 1/16; PEEK - EACH

CHR3811 Scientific Laboratory Supplies EACH 172.8 EUR

Kinesis Manifold Assembly 7 Port; 1/8; PEEK - EACH

CHR3815 Scientific Laboratory Supplies EACH 171.45 EUR

Kinesis Manifold Assembly 6 Port; 1/8; PEEK - EACH

CHR3819 Scientific Laboratory Supplies EACH 157.95 EUR

Kinesis Manifold Assembly 5 Port; 1/16; PEEK - EACH

CHR3823 Scientific Laboratory Supplies EACH 194.4 EUR

Kinesis Manifold Assembly 5 Port; 1/8; PEEK - EACH

CHR3827 Scientific Laboratory Supplies EACH 144.45 EUR

Kinesis Manifold Assembly 9 Port; 1/8; PEEK - EACH

CHR3831 Scientific Laboratory Supplies EACH 224.1 EUR

Kinesis Manifold Assembly 9 Port; 1/16; PEEK - EACH

CHR3833 Scientific Laboratory Supplies EACH 261.9 EUR

SmartWasher™ 96 Microplate Washer for 96 Well Plates, manifolds not included, 115V

MW9600 Benchmark Scientific 1 each 5109.49 EUR

SmartWasher™ 96 Microplate Washer for 96 Well Plates, manifolds not included, 230V

MW9600-E Benchmark Scientific 1 each 5109.49 EUR

Kinesis Manifold Assembly 7 Port; 1/16; PEEK; 0.02 (0.5mm) Bore - EACH

CHR3829 Scientific Laboratory Supplies EACH 207.9 EUR

J Young Gpe Dual Bank Manifold With JY Valves 3 Port 300mm Approx Width

NMR1393 Scientific Laboratory Supplies EACH 741 EUR

J Young Gpe Dual Bank Manifold With JY Valves 4 Port 400mm Approx Width

NMR1395 Scientific Laboratory Supplies EACH 905.16 EUR

J Young Gpe Dual Bank Manifold With JY Valves 5 Port 500mm Approx Width

NMR1397 Scientific Laboratory Supplies EACH 1078.44 EUR

J Young General Purpose Single Bank Vacuum Manifold With JY Valves And Vacuum Gauge Port 3 Port 300mm Approx Width

NMR1381 Scientific Laboratory Supplies EACH 449.16 EUR

J Young General Purpose Single Bank Vacuum Manifold With JY Valves And Vacuum Gauge Port 4 Port 400mm Approx Width

NMR1383 Scientific Laboratory Supplies EACH 538.08 EUR

J Young General Purpose Single Bank Vacuum Manifold With JY Valves And Vacuum Gauge Port 5 Port 500mm Approx Width

NMR1385 Scientific Laboratory Supplies EACH 628.14 EUR

J Young General Purpose Single Bank Vacuum Manifold With JY High Performance Valves And Vacuum Gauge Port 3 Port 300mm Approx Width

NMR1382 Scientific Laboratory Supplies EACH 499.32 EUR

J Young General Purpose Single Bank Vacuum Manifold With JY High Performance Valves And Vacuum Gauge Port 4 Port 400mm Approx Width

NMR1384 Scientific Laboratory Supplies EACH 606.48 EUR

J Young General Purpose Single Bank Vacuum Manifold With JY High Performance Valves And Vacuum Gauge Port 5 Port 500mm Approx Width

NMR1386 Scientific Laboratory Supplies EACH 713.64 EUR

J Young Gpe Dual Bank Manifold With JY High Performance Valves 3 Port 300mm Approx Width

NMR1394 Scientific Laboratory Supplies EACH 784.32 EUR

J Young Gpe Dual Bank Manifold With JY High Performance Valves 4 Port 400mm Approx Width

NMR1396 Scientific Laboratory Supplies EACH 970.14 EUR

Comparative thermoresistance of two biological indicators for monitoring steam autoclaves. 3. Comparison performed at 121 degrees C in a hospital prevacuum steam sterilizer

According to Pharmacopoea Nordica, steam autoclaves should be regularly monitored by a specific Swedish preparation of Bacillus stearothermophilus spores. If another biological indicator (BI) is used for such a control, it should first be calibrated against the Swedish BI (SBI) and the two BIs should be equally thermoresistant. Attest No. 1262 BI (ABI) has previously been shown to be more thermoresistant than the SBI at 134 degrees C, saturated steam. The purpose of the present study was to compare the thermoresistance of the SBI and the ABI at 121 degrees C, saturated steam and prevacuum. Seven hundred and twenty units of each BI were heat-exposed in an Emmer 760 litre prevacuum, pressure-pulsing steam autoclave.
After prevacuum with steam injection (manual or automatic preconditioning), the following incremental heat exposure times were used in triplicate (20 simultaneously tested units of each BI in each cycle) according to a randomized scheme: 5, 6 1/2, 8, 9 1/2, 11, 12 1/2, 14 and 15 min. The intra-chamber pressure and temperature were continuously monitored throughout the test and equilibration cycles.
The heat-exposed BI units were cultivated and read as recommended by the manufacturers. SBI and ABI showed a survival-time of 8 min and 11 min respectively, and a kill-time between 14 min and 15 min for both BIs. Thus, the ABI had the narrower survival-kill window. Probit analysis testing of the results showed that the difference in thermoresistance, at 121 degrees C, saturated steam and https://biodas.org/ prevacuum between Attest No. 1262 BI and the Swedish BI mentioned in Pharmacopea Nordica was not statistically significant.

Comparative thermoresistance of two biological indicators for monitoring steam autoclaves. 2. Comparison performed at 134 degrees C in a hospital prevacuum steam sterilizer

The thermoresistance of various lots of two biological indicators (BIs) for steam sterilization control, a Scandinavian BI (SBI) and the Attest BI (ABI), were compared during sterilization cycles in a hospital prevacuum (pressure-pulsing) steam autoclave at 134 degrees C, saturated steam. ABI No. 1242, ABI No. 1262 (its replacement) and incremental heat exposure times between 0 s and 180 s were used. The intrachamber temperature and pressure were continuously measured and monitored throughout the sterilization cycles.
The results showed that both of the ABIs were more thermoresistant than the SBI, giving 33.1% (ABI No. 1242), 18.9% (ABI No. 1262), and 0% (SBI) autoclave survivors. Because the time needed to reach 134 degrees C (preconditioning time) increased as the day progressed, and varied from day to day, correlation between individual incremental heat exposure times and the number of surviving BI units was not possible. Standardized test conditions are necessary for a true comparison of BIs.

Ozone: A Novel Sterilizer for Personal Protective Equipment

Objective: Personal protective equipment (PPE) is urgently sought during public health crises. It is necessary for the safety of both the patient and the healthcare professional. Yet during the recent COVID-19 pandemic, PPE scarcity in many countries, including the United States, has impacted the level of care for patients and the safety of healthcare personnel. Additionally, the implementation of mandatory mask mandates for the general public in many countries forced individuals to either reuse PPE, which can contribute to poor hygiene, or buy PPE in bulk and thereby contribute to the scarcity of PPE. In this study, we investigate the possibility of using a cost-effective ozone sterilization unit on contaminated N95 masks as an alternative to current sterilization methods.
Method: This protocol examined ozone’s ability to decontaminate N95 mask fabric that was exposed to a surrogate virus (Escherichia coli bacteriophage MS2). Once the sterilization unit achieves an ozone concentration of ~30 ppm, a 60-minute or 120-minute sterilization cycle commences. Following the sterilization cycle, we investigated the amount of viable virus on the slide using a viral plaque assay and compared it to a non-sterilized, control slide. Furthermore, we carried out trials to investigate the safety of an ozone sterilization device, by measuring the levels of ozone exposure that individuals may experience when operating the sterilization unit post-cycle.
Results: We showed that a 120-minute sterilization cycle at ~30 ppm achieves a 3-log reduction in viral activity, thereby complying with industry and U.S. Food and Drug Administration (FDA) standards. Further, we demonstrated that when following our protocol, the ozone exposure levels for a simple sterilization unit to be used at home complied with federal and industry standards.
Conclusion: Ozone may have the potential to decontaminate masks and other PPE.

Monitoring the Effective Sterilization of Low-Temperature Hydrogen Peroxide Gas Plasma Sterilizers in 58 Hospitals – 22 PLADs, China, June 2015-December 2019

What is already known on this topic?: Hydrogen peroxide sterilizeation is widely used for luminal devices. However, the low penetrability of the sterilant is of major concern.
What is added by this report?: This report investigated the effective sterilization of low-temperature hydrogen peroxide gas plasma sterilizers and compared the applicability of different biological monitoring methods based on medical luminal devices.
What are the implications for public health practice?: It is recommended to use a biological process challenge device for monitoring the sterilization of luminal devices with low-temperature hydrogen peroxide gas plasma sterilizers.

Portable sterilizer with microbe content detection device

  • Background: Infectious diseases, such as the latest COVID pandemic, caused by microorganisms like bacteria and virus, wreak havoc shaking human civilization with its rapid infection rate, and high number of mortalities. In case of a contagious disease, the virus can survive on any surface over a period of time and can be transferred to the human host through touching those surfaces unknowingly. Cleaning those possible surfaces to which these microorganisms can cling onto is one of the major ways to curb the spread. The aim of this study was to design a sterilizer which can clean such surfaces of daily used items easily within a certain period of time and can assess the cleaning efficacy by estimating the presence of microbes before and after sanitization.
  • Method development: To achieve this goal, we propose a portable sterilization unit that contains a sterilization chamber fitted with a microbe content detector. The sterilization chamber will cleanse the surfaces off the microbes using ultraviolet radiation. The chamber can be portable and at the same time big enough to accommodate items of daily use, like watch, wallet, clothes, utensils to even foods for single-house application. The microbe content detector will detect the success of the sterilization procedure by examining the time-lapse laser speckle images captured by a high-speed camera by mean of image processing algorithm, such that the user can determine whether further sterilization is required.
  • Conclusions: Microbe content detection device associated with the conventional sterilization procedure will give an assessment of the effectiveness of the sterilization. Successful implementation of sterilization for a wide variety of items of everyday use aided with microbe content detection technique is first of its kind and should be an effective tool for use in large communities, offices and public places for effective sterilization to help fight against the spread of infectious diseases.

Integrated Pre-heated 9kw boiler for Rodwell autoclaves for Rodwell autoclaves - EACH

AUT1379 Scientific Laboratory Supplies EACH 5866.39 EUR

Printer for Media Autoclaves - EACH

AUT4519 Scientific Laboratory Supplies EACH 500.86 EUR

Automatic Fill for Rodwell autoclaves - EACH

AUT1349 Scientific Laboratory Supplies EACH 1632.15 EUR

Shelf Support for Rodwell autoclaves - EACH

AUT1374 Scientific Laboratory Supplies EACH 1065.15 EUR

Fan Assisted Cooling for Rodwell autoclaves

AUT1357 Scientific Laboratory Supplies EACH 544.2 EUR

Condensate removal for Rodwell autoclaves - EACH

AUT1381 Scientific Laboratory Supplies EACH 1526.85 EUR

Printer 2 channel for Rodwell autoclaves - EACH

AUT1272 Scientific Laboratory Supplies EACH 1382.4 EUR

Condensate Collector for Rodwell autoclaves - EACH

AUT2019 Scientific Laboratory Supplies EACH 392.85 EUR

Oil Free Compressor for Rodwell autoclaves - EACH

AUT1376 Scientific Laboratory Supplies EACH 2926.8 EUR

Fan assisted cooling for Rodwell autoclaves - EACH

AUT1356 Scientific Laboratory Supplies EACH 1473.21 EUR

Drain Line Condenser for Rodwell autoclaves - EACH

AUT1358 Scientific Laboratory Supplies EACH 1518.75 EUR

Under Chamber Boiler for Rodwell autoclaves - EACH

AUT1377 Scientific Laboratory Supplies EACH 4847.04 EUR

Loading step for Ensign for Rodwell autoclaves - EACH

AUT1350 Scientific Laboratory Supplies EACH 735.75 EUR

Discard System for Genesis for Rodwell autoclaves - EACH

AUT2000 Scientific Laboratory Supplies EACH 1159.65 EUR

2 channel + pressure printer for Rodwell autoclaves - EACH

AUT1274 Scientific Laboratory Supplies EACH 1926.45 EUR

Automatic FillDrain for Clean Steam for Rodwell autoclaves - EACH

AUT1351 Scientific Laboratory Supplies EACH 2619 EUR

Discard system for Rodwell Ambassador 100 and Gemini autoclaves (per chamber) - EACH

AUT2007 Scientific Laboratory Supplies EACH 1764.45 EUR

Prestige Autoclave 2100 Extended

AUT4502 Scientific Laboratory Supplies EACH 1504.8 EUR

Sovereign Autoclave 200E - EACH

AUT0507 Scientific Laboratory Supplies EACH 31050 EUR

Sovereign Autoclave 250E - EACH

AUT0509 Scientific Laboratory Supplies EACH 31050 EUR

Prestige Autoclave 2100 Extended+ - EACH

AUT4504 Scientific Laboratory Supplies EACH 2739.31 EUR

Floor Standing Autoclave - 120L - EACH

AUT5000 Scientific Laboratory Supplies EACH 36907.65 EUR

Floor Standing Autoclave - 153L - EACH

AUT5002 Scientific Laboratory Supplies EACH 40979.25 EUR

Floor Standing Autoclave - 247L - EACH

AUT5004 Scientific Laboratory Supplies EACH 45276.3 EUR

Floor Standing Autoclave - 290L - EACH

AUT5006 Scientific Laboratory Supplies EACH 48340.8 EUR

Floor Standing Autoclave - 344L - EACH

AUT5008 Scientific Laboratory Supplies EACH 50566.95 EUR

Design and development of heater control circuit without temperature sensor for monitoring hydrogen in argon

A thin film based tin oxide sensor is developed to monitor low levels of hydrogen (concentration ranging from 5 to 75 ppm) in the cover gas plenum of the fast breeder test reactor. The heater and the sensor patterns are integrated on a miniature alumina substrate, and necessary electrical leads are incorporated into it. For proper functioning of the sensor, the heater has to be maintained at a constant temperature of 350 °C. This paper gives an outline of the electronics developed to measure the sensor signal and to control the heater temperature.
The major challenge in this work is that there was no provision for embedding a temperature sensor on the heater surface due to physical constraints. This constrained the maintenance of a constant heater temperature for the proper functioning of the sensor. This led us to develop and demonstrate a heater control circuit without a temperature sensor to maintain a fixed temperature for https://biodas.org/ monitoring hydrogen in argon, and electronics for the above-mentioned circuitry is discussed.

ERC-ESICM guidelines on temperature control after cardiac arrest in adults

  • The aim of these guidelines is to provide evidence‑based guidance for temperature control in adults who are comatose after resuscitation from either in-hospital or out-of-hospital cardiac arrest, regardless of the underlying cardiac rhythm. These guidelines replace the recommendations on temperature management after cardiac arrest included in the 2021 post-resuscitation care guidelines co-issued by the European Resuscitation Council (ERC) and the European Society of Intensive Care Medicine (ESICM).
  • The guideline panel included thirteen international clinical experts who authored the 2021 ERC-ESICM guidelines and two methodologists who participated in the evidence review completed on behalf of the International Liaison Committee on Resuscitation (ILCOR) of whom ERC is a member society. We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and grade recommendations. The panel provided suggestions on guideline implementation and identified priorities for future research. The certainty of evidence ranged from moderate to low.
  • In patients who remain comatose after cardiac arrest, we recommend continuous monitoring of core temperature and actively preventing fever (defined as a temperature > 37.7 °C) for at least 72 h. There was insufficient evidence to recommend for or against temperature control at 32-36 °C or early cooling after cardiac arrest. We recommend not actively rewarming comatose patients with mild hypothermia after return of spontaneous circulation (ROSC) to achieve normothermia. We recommend not using prehospital cooling with rapid infusion of large volumes of cold intravenous fluids immediately after ROSC.

Thermal Model of an Omnimagnet for Performance Assessment and Temperature Control

An Omnimagnet is an electromagnetic device that enables remote magnetic manipulation of devices such as medical implants and microrobots. It is composed of three orthogonal nested solenoids with a ferromagnetic core at the center. Electrical current within the solenoids leads to undesired temperature increase within the Omnimagnet. If the temperature exceeds the melting point of the wire insulation, device failure may occur. Thus, a study of heat transfer within an Omnimagnet is a necessity, particularly to maximize the performance of the device. A transient heat transfer model that incorporates all three heat transfer modes is proposed and experimentally validated with an average normalized root-mean-square error of less than 4% (data normalized by temperature in degree celsius). The transient model is not computationally expensive and is applicable to Omnimagnets with different structures. The code is applied to calculate the maximum safe operational time at a fixed input current or the maximum safe input current for a fixed time interval. The maximum safe operational time and maximum safe input current depend on size and structure of the Omnimagnet and the lowest critical temperature of all the Omnimagnet materials. A parametric study shows that increasing convective heat transfer during cooling, and during heating with low input currents, is an effective method to increase the maximum operational time of the Omnimagnet. The thermal model is also presented in a state-space equation format that can be used in a real-time Kalman filter current controller to avoid device failure due to excessive heating.

Integrated Temperature and Position Sensors in a Shape-Memory Driven Soft Actuator for Closed-Loop Control

Soft actuators are a promising option for the advancing fields of human-machine interaction and dexterous robots in complex environments. Shape memory alloy wire actuators can be integrated into fiber rubber composites for highly deformable structures. For autonomous, closed-loop control of such systems, additional integrated sensors are necessary. In this work, a soft actuator is presented that incorporates fiber-based actuators and sensors to monitor both deformation and temperature.
The soft actuator showed considerable deformation around two solid body joints, which was then compared to the sensor signals, and their correlation was analyzed. Both, the actuator as well as the sensor materials were processed by braiding and tailored fiber placement before molding with silicone rubber. Finally, the novel fiber-rubber composite material was used to implement closed-loop control of the actuator with a maximum error of 0.5°.

Surface temperature controls the pattern of post-earthquake landslide activity

The patterns and controls of the transient enhanced landsliding that follows strong earthquakes remain elusive. Geostatistical models can provide clues on the underlying processes by identifying relationships with a number of physical variables. These models do not typically consider thermal information, even though temperature is known to affect the hydro-mechanical behavior of geomaterials, which, in turn, controls slope stability. Here, we develop a slope unit-based multitemporal susceptibility model for the epicentral region of the 2008 Wenchuan earthquake to explore how land surface temperature (LST) relates to landslide patterns over time. 3
We find that LST can explain post-earthquake landsliding while it has no visible effect on the coseismic scene, which is dominated by the strong shaking. Specifically, as the landscape progressively recovers and landslide rates decay to pre-earthquake levels, a positive relationship between LST and landslide persistence emerges. This seems consistent with the action of healing processes, capable of restoring the thermal sensitivity of the slope material after the seismic disturbance. Although analyses in other contexts (not necessarily seismic) are warranted, we advocate for the inclusion of thermal information in geostatistical modeling as it can help form a more physically consistent picture of slope stability controls.

Stuart Temperature Controller SCT1 - EACH

STI5500 Scientific Laboratory Supplies EACH 384.75 EUR

Heidolph Electronic Temperature Controller EKT SS Sensor - EACH

STI2100 Scientific Laboratory Supplies EACH 876.87 EUR

Eppendorf Centrifuge 5702RH temperature controlled without rotor - EACH

E5704000060 Scientific Laboratory Supplies EACH 6107.4 EUR

Temp-O-Trol digital temperature control for use with platinum RTD sensor (not included), 1800W, 120V

108ATOTL9-1800RTD Glascol each 1541 EUR

DigiTrol, auto tuning temperature control, digital readout, with universal input, 0-750C, 1800W, 120V

104APL612 Glascol each 1121 EUR

DigiTrol, auto tuning temperature control, digital readout, with type J thermocouple. 0-750C, 2400W, 240V

104APL624 Glascol each 1290 EUR

DigiTrol, auto tuning temperature control, digital readout, with type K thermocouple. -200-1250C, 2400W, 240V

104APL624K Glascol each 1290 EUR

DigiTrol, auto tuning temperature control, digital readout, with type T thermocouple. -200-350C, 2400W, 240V

104APL624T Glascol each 1290 EUR

Eppendorf Centrifuge 5702RH temperature controlled without rotor- IVD Only - EACH

E5704000067 Scientific Laboratory Supplies EACH 6413.85 EUR

DigiTrol, auto tuning temperature control, digital readout, with type J thermocouple. 0-750C, 2400W, 240V, CE

104APL624CE Glascol each 1353 EUR

DigiTrol, auto tuning temperature control, digital readout, with type K thermocouple. -200-1250C, 2400W, 240V, CE

104APL624KCE Glascol each 1353 EUR

DigiTrol, auto tuning temperature control, digital readout, with type T thermocouple. -200-350C, 2400W, 240V, CE

104APL624TCE Glascol each 1353 EUR

Temperature Probe

2-128-0006 Biologics each 266 EUR

Temp-O-Trol digital temperature control with thermocouple input - for type J thermocouple (not included). 1800W, 120V

108ATOTL9-1800TCJ Glascol each 1541 EUR

Temp-O-Trol digital temperature control with thermocouple input - for type K thermocouple (not included). 1800W, 120V

108ATOTL9-1800TCK Glascol each 1541 EUR

Temp-O-Trol digital temperature control with thermocouple input - for type T thermocouple (not included). 1800W, 120V

108ATOTL9-1800TCT Glascol each 1541 EUR

External Temperature Probe

BSH-TP1 Benchmark Scientific 1 PC 234.84 EUR

Temperature Probe 400oc - EACH

HEA5262 Scientific Laboratory Supplies EACH 510.3 EUR

Temperature Probe 800oc - EACH

HEA5264 Scientific Laboratory Supplies EACH 569.7 EUR

Agarose, Low Melt Temperature

40100156-1 Glycomatrix 10 g 68.53 EUR

Agarose, Low Melt Temperature

40100156-2 Glycomatrix 25 g 136.81 EUR

Agarose, Low Melt Temperature

40100156-3 Glycomatrix 50 g 258.28 EUR

Superhydrophobic paper in the development of disposable labware and lab-on-paper devices

Traditionally in superhydrophobic surfaces history, the focus has frequently settled on the use of complex processing methodologies using nonbiodegradable and costly materials. In light of recent events on lab-on-paper emergence, there are now some efforts for the production of superhydrophobic paper but still with little development and confined to the fabrication of flat devices. This work gives a new look at the range of possible applications of bioinspired superhydrophobic paper-based substrates, obtained using a straightforward surface modification with poly(hydroxybutyrate). As an end-of-proof of the possibility to create lab-on-chip portable devices, the patterning of superhydrophobic paper with different wettable shapes is shown with low-cost approaches.
Furthermore, we suggest the use of superhydrophobic paper as an extremely low-cost material to design essential nonplanar lab apparatus, including reservoirs for liquid storage and manipulation, funnels, tips for pipettes, or accordion-shaped substrates for liquid transport or mixing. Such devices take the advantage of the self-cleaning and extremely water resistance properties of the surfaces https://biodas.org/ as well as the actions that may be done with paper such as cut, glue, write, fold, warp, or burn. The obtained substrates showed lower propensity to adsorb proteins than the original paper, kept superhydrophobic character upon ethylene oxide sterilization and are disposable, suggesting that the developing devices could be especially adequate for use in contact with biological and hazardous materials.

Contaminating levels of zinc found in commonly-used labware and buffers affect glycine receptor currents

Zinc is an allosteric modulator of glycine receptor function, enhancing the effects of glycine at nM to low μM concentrations, and inhibiting its effects at higher concentrations. Because of zinc’s high potency at the glycine receptor, there exists a possibility that effects attributed solely to exogenously-applied glycine in fact contain an undetected contribution of zinc acting as an allosteric modulator. We found that glycine solutions made up in standard buffers and using deionized distilled water produced effects that could be decreased by the zinc chelator tricine.
This phenomenon was observed in three different vials tested and persisted even if vials were extensively washed, suggesting the zinc was probably present in the buffer constituents. In addition, polystyrene, but not glass, pipets bore a contaminant that enhanced glycine receptor function and that could also be antagonized by tricine. Our findings suggest that without checking for this effect using a chelator such as tricine, one cannot assume that responses elicited by glycine applied alone are not necessarily also partially due to some level of allosteric modulation by zinc.

Labware additives identified to be selective monoamine oxidase-B inhibitors

Plastic labware is used in all processes of modern pharmaceutical research, including compound storage and biological assays. The use of these plastics has created vast increases in productivity and cost savings as experiments moved from glass test tubes and capillary pipettes to plastic microplates and multichannel liquid handlers. One consequence of the use of plastic labware, however, is the potential release of contaminants and their resultant effects on biological assays.
We report herein the identification of biologically active substances released from a commonly used plastic microplate. The active contaminants were identified by gas chromatography-mass spectroscopy as dodecan-1-ol, dodecyl 3-(3-dodecoxy-3-oxopropyl)sulfanylpropanoate, and dodecanoic acid, and they were found to be selective monoamine oxidase-B inhibitors.

Open Labware: 3-D printing your own lab equipment

The introduction of affordable, consumer-oriented 3-D printers is a milestone in the current “maker movement,” which has been heralded as the next industrial revolution. Combined with free and open sharing of detailed design blueprints and accessible development tools, rapid prototypes of complex products can now be assembled in one’s own garage–a game-changer reminiscent of the early days of personal computing. At the same time, 3-D printing has also allowed the scientific and engineering community to build the “little things” that help a lab get up and running much faster and easier than ever before.

3D Printing in the Laboratory: Maximize Time and Funds with Customized and Open-Source Labware

3D-Printed Labware for High-Throughput Immobilization of Enzymes

  1. In continuous flow biocatalysis, chemical transformations can occur under milder, greener, more scalable, and safer conditions than conventional organic synthesis. However, the method typically involves extensive screening to optimize each enzyme’s immobilization on its solid support material. The task of weighing solids for large numbers of experiments poses a bottleneck for screening enzyme immobilization conditions.
  2. For example, screening conditions often require multiple replicates exploring different support chemistries, buffer compositions, and temperatures. Thus, we report 3D-printed labware designed to measure and handle solids in multichannel format and expedite screening of enzyme immobilization conditions.
  3. To demonstrate the generality of these advances, alkaline phosphatase, glucose dehydrogenase, and laccase were screened for immobilization efficiency on seven resins. The results illustrate the requirements for optimization of each enzyme’s loading and resin choice for optimal catalytic performance. Here, 3D-printed labware can decrease the requirements for an experimentalist’s time by >95%.
  4. The approach to rapid optimization of enzyme immobilization is applicable to any enzyme and many solid support resins. Furthermore, the reported devices deliver precise and accurate aliquots of essentially any granular solid material.

Adsorption of bacteriophages on polypropylene labware affects the reproducibility of phage research

Hydrophobicity is one of the most critical factors governing the adsorption of molecules and objects, such as virions, on surfaces. Even moderate change of wetting angle of plastic surfaces causes a drastic decrease ranging from 2 to 5 logs of the viruses (e.g., T4 phage) in the suspension due to adsorption on polymer vials’ walls. The effect varies immensely in seemingly identical containers but purchased from different vendors. Comparison of glass, polyethylene, polypropylene, and polystyrene containers revealed a threshold in the wetting angle of around 95°: virions adsorb on the surface of more hydrophobic containers, while in more hydrophilic vials, phage suspensions are stable.
The polypropylene surface of the Eppendorf-type and Falcon-type can accommodate from around 108 PFU/ml to around 1010 PFU/ml from the suspension. The adsorption onto the container’s wall might result in complete scavenging of virions from the bulk. We developed two methods to overcome this issue. The addition of surfactant Tween20 and/or plasma treatment provides a remedy by modulating surface wettability and inhibiting virions’ adsorption. Plastic containers are essential consumables in the daily use of many bio-laboratories. Thus, this is important not only for phage-related research (e.g., the use of phage therapies as an alternative for antibiotics) but also for data comparison and reproducibility in the field of biochemistry and virology.

Benchmark Agarose LE, 25g

A1700 Benchmark Scientific 1 PC 57.99 EUR

Benchmark Agarose LE, 100g

A1701 Benchmark Scientific 1 PC 139.87 EUR

Benchmark Agarose LE, 500g

A1705 Benchmark Scientific 1 PC 487.4 EUR

Benchmark Agarose 3:1, 100g

A1801-31 Benchmark Scientific 1 PC 295.61 EUR

Benchmark SureAir Replacement Filter

B5200-FIL Benchmark Scientific each 307.97 EUR

Benchmark Agarose LM, Low Melt, 100g

A1801-LM Benchmark Scientific 1 PC 388.41 EUR

Benchmark SureAir Replacement Prefilter

B5200-PRE Benchmark Scientific each 50.47 EUR

Benchmark SureAir PCR Workstation, 115V

B5200 Benchmark Scientific each 2279.7 EUR

Benchmark SureAir PCR Workstation, 230V

B5200-E Benchmark Scientific each 2279.7 EUR

Benchmark Agarose HR, PCR Grade for DNA fragments between 20 to 800bp, 100g

A1801-HR Benchmark Scientific 1 PC 335.88 EUR

Micro Labware Kit

LA025-1NO EWC Diagnostics 1 unit 16.29 EUR

Micro Labware Kit

LA025-5NO EWC Diagnostics 1 unit 72.8 EUR

Benchmark Printer 230V - EACH

AUT2743 Scientific Laboratory Supplies EACH 549.33 EUR

Benchmark Digital Hotplate 230V - EACH

MIX1262 Scientific Laboratory Supplies EACH 468.45 EUR

Benchmark Orbi-Shaker CO2 230V - EACH

MIX7260 Scientific Laboratory Supplies EACH 5819.85 EUR

Benchmark Hotplate 17.8cm x 17.8cm 230V - EACH

MIX1301 Scientific Laboratory Supplies EACH 438.75 EUR

Benchmark Replacement Cap Blue 50mL - PK10

BOT1910 Scientific Laboratory Supplies PK10 52.65 EUR

Benchmark Refill Glass Beads 3mm 1000g - EACH

STE1042 Scientific Laboratory Supplies EACH 47.39 EUR

Benchmark Digital Magnetic Stirrer 230V - EACH

MIX1263 Scientific Laboratory Supplies EACH 468.45 EUR

Benchmark MiniMag Magnetic Stirrer 240V - EACH

MIX1290 Scientific Laboratory Supplies EACH 199.8 EUR

Benchmark MyFuge 5 MicroCentrifuge 230V - EACH

CEN1870 Scientific Laboratory Supplies EACH 788.4 EUR

Benchmark Replacement Sealing Ring 50mL - PK10

BOT1911 Scientific Laboratory Supplies PK10 22.95 EUR

Benchmark Magnetic Stirrer 17.8cm x 17.8cm 230V - EACH

MIX1302 Scientific Laboratory Supplies EACH 438.75 EUR

Benchmark StripSpin 12 Mini Centrifuge 230V - EACH

CEN1714 Scientific Laboratory Supplies EACH 571.05 EUR

Contaminating levels of zinc found in commonly-used labware and buffers affect glycine receptor currents

Zinc is an allosteric modulator of glycine receptor function, enhancing the effects of glycine at nM to low μM concentrations, and inhibiting its effects at higher concentrations. Because of zinc’s high potency at the glycine receptor, there exists a possibility that effects attributed solely to exogenously-applied glycine in fact contain an undetected contribution of zinc acting as an allosteric modulator. We found that glycine solutions made up in standard buffers and using deionized distilled water produced effects that could be decreased by the zinc chelator tricine.
This phenomenon was observed in three different vials tested and persisted even if vials were extensively washed, suggesting the zinc was probably present in the buffer constituents. In addition, polystyrene, but not glass, pipets bore a contaminant that enhanced glycine receptor function and that could also be antagonized by tricine. Our findings suggest that without checking for this effect using a chelator such as tricine, one cannot assume that responses elicited by glycine applied alone are not necessarily also partially due to some level of allosteric modulation by zinc.

Superhydrophobic paper in the development of disposable labware and lab-on-paper devices

Traditionally in superhydrophobic surfaces history, the focus has frequently settled on the use of complex processing methodologies using nonbiodegradable and costly materials. In light of recent events on lab-on-paper emergence, there are now some efforts for the production of superhydrophobic paper https://biodas.org/ but still with little development and confined to the fabrication of flat devices. This work gives a new look at the range of possible applications of bioinspired superhydrophobic paper-based substrates, obtained using a straightforward surface modification with poly(hydroxybutyrate). As an end-of-proof of the possibility to create lab-on-chip portable devices, the patterning of superhydrophobic paper with different wettable shapes is shown with low-cost approaches.
Furthermore, we suggest the use of superhydrophobic paper as an extremely low-cost material to design essential nonplanar lab apparatus, including reservoirs for liquid storage and manipulation, funnels, tips for pipettes, or accordion-shaped substrates for liquid transport or mixing. Such devices take the advantage of the self-cleaning and extremely water resistance properties of the surfaces as well as the actions that may be done with paper such as cut, glue, write, fold, warp, or burn. The obtained substrates showed lower propensity to adsorb proteins than the original paper, kept superhydrophobic character upon ethylene oxide sterilization and are disposable, suggesting that the developing devices could be especially adequate for use in contact with biological and hazardous materials.

3D Printing in the Laboratory: Maximize Time and Funds with Customized and Open-Source Labware

3D-Printed Labware for High-Throughput Immobilization of Enzymes

In continuous flow biocatalysis, chemical transformations can occur under milder, greener, more scalable, and safer conditions than conventional organic synthesis. However, the method typically involves extensive screening to optimize each enzyme’s immobilization on its solid support material. The task of weighing solids for large numbers of experiments poses a bottleneck for screening enzyme immobilization conditions. For example, screening conditions often require multiple replicates exploring different support chemistries, buffer compositions, and temperatures.
Thus, we report 3D-printed labware designed to measure and handle solids in multichannel format and expedite screening of enzyme immobilization conditions. To demonstrate the generality of these advances, alkaline phosphatase, glucose dehydrogenase, and laccase were screened for immobilization efficiency on seven resins. The results illustrate the requirements for optimization of each enzyme’s loading and resin choice for optimal catalytic performance. Here, 3D-printed labware can decrease the requirements for an experimentalist’s time by >95%. The approach to rapid optimization of enzyme immobilization is applicable to any enzyme and many solid support resins. Furthermore, the reported devices deliver precise and accurate aliquots of essentially any granular solid material.

Additive manufactured customizable labware for biotechnological purposes

Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor

The severe acute respiratory syndrome virus-2 (SARS CoV-2) infection has resulted in the current global pandemic. The binding of SARS CoV-2 spike protein receptor-binding domain (RBD) to the human angiotensin converting enzyme-2 (ACE-2) receptor causes the host infection. The spike protein has undergone several mutations with reference to the initial strain isolated during December 2019 from Wuhan, China. A number of these mutant strains have been reported as variants of concern and as variants being monitored. Some of these mutants are known to be responsible for increased transmissibility of the virus.
The reason for the increased transmissibility caused by the point mutations can be understood by studying the structural implications and inter-molecular interactions in the binding of viral spike protein RBD and human ACE-2. Here, we use the crystal structure of the RBD in complex with ACE-2 available in www.joplink.net/coronavirus-proteins/ the public domain and analyse the 250 ns molecular dynamics (MD) simulations of wild-type and mutants; K417N, K417T, N440K, N501Y, L452R, T478K, E484K and S494P.
The ionic, hydrophobic and hydrogen bond interactions, amino acid residue flexibility, binding energies and structural variations are characterized. The MD simulations provide clues to the molecular mechanisms of ACE-2 receptor binding in wild-type and mutant complexes. The mutant spike proteins RBD were associated with greater binding affinity with ACE-2 receptor. Communicated by Ramaswamy H. Sarma.

COVID-19 and Alzheimer’s disease: Meninges-mediated neuropathology

SARS-CoV-2 the causative agent of COVID-19 displays a broad range of pathophysiology. Cytokine storms associated with COVID-19 damage the blood-brain barrier (BBB) and allow pro-inflammatory factors to invade the brain, further promoting neurodegeneration. While SARS-CoV-2 viral RNA and proteins have been detected in brain tissues, the mechanisms of neuroinvasion remain unknown. COVID-19 has had a disproportionate impact on those suffering from neurodegenerative disorders such as Alzheimer’s disease (AD).
Understanding the mechanisms of SARS-CoV-2 neuroinvasion is crucial to study the long-term neurocognitive effects of COVID-19 on AD pathology.
Viruses can infiltrate the brain through the meninges via infected immune cells. The meninges regulate the immune surveillance of the brain and play a key role in the efflux of pathogens from the brain. Meningeal dysfunction has been demonstrated to exacerbate amyloid-beta pathogenesis. In this study, we explore the neuroinvasion pathway of SARS-CoV-2 through the meninges and its effect on AD pathology.
Method: 5x FAD x hACE2 mice were inoculated intranasally with a sublethal dose of SARS-CoV-2. The mice were maintained for 2 weeks. Mouse brains and meninges were harvested. The tissue was stained and immunofluorescence imaging was conducted to study viral proliferation and immune responses. Histo-cytometry was conducted for quantitative imaging analysis. Gene expression studies were done using Nanostring assays. All experiments involving the SARS-Cov-2 virus were carried out in a BSL3 facility.
Result: This ongoing study demonstrates the proliferation of the SARS-CoV-2 virus in the brain via meningeal lymphatics. SARS-CoV-2 infection resulted in increased neuroinflammation. Additionally, inflammatory responses induced meningeal dysfunction resulting in increased amyloid-beta pathology and cerebrospinal fluid drainage.
Conclusion: Given the increasing evidence for a viral hypothesis of Alzheimer’s Disease it is extremely important to study the neurodegenerative effects of COVID-19 which has affected millions worldwide. We demonstrate that SARS-CoV-2 infiltrates the brain via the meninges promoting neuroinflammation. Furthermore, amyloid-beta pathologies are exacerbated by COVID-19 in animal models providing preclinical evidence of the long-term neurodegenerative effects of COVID-19.

Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by beta-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has rapidly spread across the globe starting from February 2020. It is well established that during viral infection, extracellular vesicles become delivery/presenting vectors of viral material. However, studies regarding extracellular vesicle function in COVID-19 pathology are still scanty. Here, we performed a comparative study on exosomes recovered from the plasma of either MILD or SEVERE COVID-19 patients.
We show that although both types of vesicles efficiently display SARS-CoV-2 spike-derived peptides and carry immunomodulatory molecules, only those of MILD patients are capable of efficiently regulating antigen-specific CD4+ T-cell responses. Accordingly, by mass spectrometry, we show that the proteome of exosomes of MILD patients correlates with a proper functioning of the immune system, while that of SEVERE patients is associated with increased and chronic inflammation.
Overall, we show that exosomes recovered from the plasma of COVID-19 patients possess SARS-CoV-2-derived protein material, have an active role in enhancing the immune response, and possess a cargo that reflects the pathological state of patients in the acute phase of the disease.

Role of SARS-CoV-2 in causing blood-brain barrier leakage and microglial activation as a risk factor of cognitive deterioration in subjects at risk of Alzheimer’s disease

The recent pandemic provides evidence of altered central nervous system (CNS) function in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-COV-2 invades the CNS by binding angiotensin-converting enzyme 2 (ACE2) expressed on neurons and glia. SARS-COV-2 may have effects on increased permeability of endothelial cells within the blood-brain barrier (BBB) as studies have shown that the S1 protein can transverse the BBB.
This is interesting because leakage of the BBB is implicated in Alzheimer’s disease (AD) pathogenesis. We hypothesized that SARS-CoV-2 infection leads to innate stimulated inflammation, ultimately activating microglial cells and an influx of pro-inflammatory cytokines and leukocytes in the meninges, contributing to increased permeability of the BBB. This BBB permeability increases AD susceptibility in subjects at risk by causing irreversible damage to the BBB and microglial cell activation.
Method: We developed a double transgenic mouse model using mice expressing human ACE2 receptor and 5xFAD mice that exhibit increased neuropathology seen in human AD allowing modeling of AD in SARS-CoV-2 pathogenesis. The hACE2/5xFAD double transgenic mice were intranasally inoculated with a sub-lethal dose of SARS-CoV-2 to test the hypothesis that SARS-COV-2 potentiates AD pathology and cognitive deterioration through impairment of the BBB. Leukocyte and cytokine populations were measured by flow cytometry and single-nuclei RNA sequencing of the meninges for characterization of microglial populations.
Result: SARS-CoV-2 creates a cytotoxic environment in the brain immediately following infection in hACE2/5xFAD mice leading to leakage of the BBB in the meninges. Activation of microglial innate cells by SARS-COV-2 invasion of the CNS will cause neural deterioration having long term implications on cognitive function. The hACE2/5xFAD mouse model allows us to uncover implications for SARS-COV-2 on AD cognitive deterioration.
Conclusion: The hACE2/5xFAD mouse allows modeling of SARS-CoV-2 in developing AD cases and allowed us to determine the immune environment generated in the meninges in response to SARS-CoV-2 infections. This mouse model provides a platform to proactively determine the effects of SARS-CoV-2 in developing AD cases, a methodology to be exploited for future mouse models determining the relationship of other viruses on AD pathology, and the opportunity to address phenotypes with therapeutics for preventative initiatives.

Recombinant SARS SARS MERS Protein, His, E.coli-1mg

1mg 1513.2 EUR

Recombinant SARS SARS-CoV Protein, His, E.coli-1mg

1mg 4744.8 EUR

Recombinant SARS SARS-CoV Protein, His, E.coli-5ug

5ug 186 EUR

Recombinant SARS SARS MERS Protein, His, E.coli-100ug

100ug 261.6 EUR

Recombinant SARS SARS MERS Protein, His, E.coli-500ug

500ug 795.6 EUR

Recombinant SARS SARS-CoV Protein, His, E.coli-20ug

20ug 241.2 EUR

Recombinant SARS SARS Spike S1 Protein, Avi His Tag

20ug 495 EUR

Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg

1mg 1273.2 EUR

Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg

1mg 1273.2 EUR

Recombinant SARS SARS Spike RBD Protein, Avi His Tag

20ug 495 EUR

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.

Platinum-based chemotherapy is the mainstay of front-line therapy of sufferers affected by pluri-metastatic intermediate/excessive grade NeuroEndocrine Neoplasms (NENs). Nevertheless, there aren’t any commonplace second-line remedies at illness development.

Earlier scientific experiences have evidenced that temozolomide (TMZ), an oral analog of dacarbazine, is lively in opposition to NENs at commonplace doses of 150 to 200 mg/mq per day on days 1 to five of a 28-day cycle, even when a major treatment-related toxicity is reported.

METHODS

Metastatic NENs sufferers had been handled on the ENETS (European NeuroEndocrine Tumor Society) heart of excellence of Naples (Italy), from 2014 to 2017 with a second-line various metronomic schedule of TMZ, 75 mg/m2per os “one week on/one week off”. Toxicity was graded with NCI-CTC standards v4.0; goal responses with RECIST v1.1 and efficiency standing (PS) in accordance with ECOG.

Twenty-six consecutive sufferers had been handled. Median age was 65.5 years. The predominant main organs had been pancreas and lung. Grading was G2 in 11 sufferers, G3 in 15. Greater than half of sufferers had a PS 2 (15 vs. 11 with PS 1). The median time-on-temozolomide remedy was 12.2 months (95% CI: 11.4-19.6). No G3/G4 toxicities had been registered.

Full response was obtained in 1 affected person, partial response in 4, steady illness in 19 (illness management price: 92.3%), and progressive illness in 2. The median total survival from TMZ begin was 28.Three months. PS improved in 73% of sufferers.Metronomic TMZ is an acceptable therapy for G2 and G3 NENs significantly in PS 2 sufferers. Potential and bigger trials are wanted to verify these outcomes.

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.
Security and Exercise of Metronomic Temozolomide in Second-Line Remedy of Superior Neuroendocrine Neoplasms.

Would ivermectin for malaria management be useful in onchocerciasis-endemic areas?

There may be accumulating proof supporting using ivermectin as a malaria management software. Latest findings from the repeat ivermectin mass drug administrations for management of malaria trial demonstrated a diminished incidence of malaria in villages which obtained repeated ivermectin mass drug administration (MDA; six doses) in comparison with those that had just one spherical of ivermectin.

EEF1A2 siRNA

20-abx901643
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

EEF1A2 Peptide

43-205P 0.1 mg
EUR 405.6

EEF1A2 Antibody

45965-100ul 100ul
EUR 302.4

EEF1A2 Antibody

45965-50ul 50ul
EUR 224.4

EEF1A2 Antibody

DF9493 200ul
EUR 420

EEF1A2 Antibody

DF9493-100ul 100ul
EUR 280

EEF1A2 Antibody

DF9493-200ul 200ul
EUR 350

EEF1A2 antibody

E39-10409 100ug/100ul
EUR 225
Description: Available in various conjugation types.

eEF1A2 Antibody

E92473 100ul
EUR 255
Description: Available in various conjugation types.

EEF1A2 Antibody

E311602 200ul
EUR 275
Description: Available in various conjugation types.

EEF1A2 Antibody

E19-9493-1 50ug/50ul
EUR 145
Description: Available in various conjugation types.

EEF1A2 Antibody

E19-9493-2 100ug/100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 antibody

70R-17001 50 ul
EUR 289
Description: Rabbit polyclonal EEF1A2 antibody

EEF1A2 antibody

70R-3046 50 ug
EUR 467
Description: Rabbit polyclonal EEF1A2 antibody raised against the middle region of EEF1A2

EEF1A2 Antibody

AF6618 100ul
EUR 420

EEF1A2 Antibody

AF6618-100ul 100ul
EUR 280

EEF1A2 Antibody

AF6618-200ul 200ul
EUR 350

EEF1A2 Antibody

1-CSB-PA007412ESR1HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against EEF1A2. Recognizes EEF1A2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200

EEF1A2 Antibody

1-CSB-PA007412ESR2HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against EEF1A2. Recognizes EEF1A2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200

EEF1A2 Antibody

1-CSB-PA007412GA01HU
  • Ask for price
  • Ask for price
  • 150ul
  • 50ul
Description: A polyclonal antibody against EEF1A2. Recognizes EEF1A2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC

EEF1A2 Antibody

ABD9493 100 ug
EUR 525.6

EEF1A2 Antibody

GWB-MR059E 50ug Ask for price

EEF1A2 Antibody

R34872-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Eukaryotic translation elongation factor 1 alpha 2, EEF1AL, EF-1-alpha-2; EEF1A2

EEF1A1 / EEF1A2 / EEF1A1P5 Antibody

20-abx327705
  • Ask for price
  • Ask for price
  • 100 ug
  • 50 ug

EEF1A1/EEF1A2/EEF1A1P5 Antibody

1-CSB-PA005918
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against EEF1A1/EEF1A2/EEF1A1P5. Recognizes EEF1A1/EEF1A2/EEF1A1P5 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

EEF1A1 / EEF1A2 / EEF1A1P5 Antibody

abx327705-100g 100 µg
EUR 250

EEF1A1 / EEF1A2 / EEF1A1P5 Antibody

abx327705-50g 50 µg
EUR 187.5

EEF1A2 Rabbit pAb

A7327-100ul 100 ul
EUR 369.6

EEF1A2 Rabbit pAb

A7327-200ul 200 ul
EUR 550.8

EEF1A2 Rabbit pAb

A7327-20ul 20 ul
EUR 219.6

EEF1A2 Rabbit pAb

A7327-50ul 50 ul
EUR 267.6

EEF1A2 Rabbit pAb

E2502473 100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 Rabbit pAb

E2507327 100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 Rabbit pAb

A2473-100ul 100 ul
EUR 369.6

EEF1A2 Rabbit pAb

A2473-200ul 200 ul
EUR 550.8

EEF1A2 Rabbit pAb

A2473-20ul 20 ul
EUR 219.6

EEF1A2 Rabbit pAb

A2473-50ul 50 ul
EUR 267.6

Human EEF1a2 Protein

20-abx650911
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

anti- EEF1A2 antibody

FNab02642 100µg
EUR 606.3
Description: Antibody raised against EEF1A2

Human EEF1a2 Protein

abx650911-5mg 5 mg
EUR 337.5

EEF1A2 Blocking Peptide

33R-9588 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EEF1A2 antibody, catalog no. 70R-3046

EEF1A2 Blocking Peptide

DF9493-BP 1mg
EUR 234

Recombinant Human EEF1A2

P0565 100ug
EUR 626.83
Description: Recombinant Human protein for EEF1A2

EEF1A2 Polyclonal Antibody

E97327 100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 Conjugated Antibody

C45965 100ul
EUR 476.4

EEF1A2 Polyclonal Antibody

E-AB-61648-120uL 120uL
EUR 320
Description: Unconjugated

EEF1A2 Polyclonal Antibody

E-AB-61648-200uL 200uL
EUR 530
Description: Unconjugated

EEF1A2 Polyclonal Antibody

E-AB-61648-60uL 60uL
EUR 200
Description: Unconjugated

EEF1A2 Polyclonal Antibody

E-AB-61648-each each Ask for price
Description: Unconjugated

EEF1A2 ELISA KIT|Human

EF009296 96 Tests
EUR 826.8

Rat EEF1A2 shRNA Plasmid

20-abx984646
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Mouse EEF1A2 shRNA Plasmid

20-abx970114
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Human EEF1A2 shRNA Plasmid

20-abx951333
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

EEF1A2 (untagged)-Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2)

SC118902 10 µg Ask for price

EEF1A2 Recombinant Protein (Rat)

RP199082 100 ug Ask for price

OACA08309-50UL - EEF1A2 Antibody

OACA08309-50UL 50ul
EUR 189

OACA08310-50UL - EEF1A2 Antibody

OACA08310-50UL 50ul
EUR 189

OAAN02225-50UL - EEF1A2 Antibody

OAAN02225-50UL 50ul
EUR 149

EEF1A2 Recombinant Protein (Human)

RP010195 100 ug Ask for price

EEF1A2 Recombinant Protein (Mouse)

RP130898 100 ug Ask for price

Eef1a2 (untagged) - Mouse eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), (10ug)

MC216235 10 µg Ask for price

Eef1a2 (GFP-tagged) - Mouse eukaryotic translation elongation factor 1 alpha 2 (Eef1a2)

MG207396 10 µg Ask for price

EEF1A2 (GFP-tagged) - Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2)

RG210716 10 µg Ask for price

EEF1A2 Rabbit Polyclonal Antibody

55180 100ul
EUR 439

OACA08309-100UL - EEF1A2 Antibody

OACA08309-100UL 100ul
EUR 230

OACA08310-100UL - EEF1A2 Antibody

OACA08310-100UL 100ul
EUR 230

OAAN02225-100UL - EEF1A2 Antibody

OAAN02225-100UL 100ul
EUR 249

OAAN02225-200UL - EEF1A2 Antibody

OAAN02225-200UL 200ul
EUR 389

OAGA01881-100UL - EEF1A2 Antibody

OAGA01881-100UL 100ul
EUR 369

OAGA01882-100UL - EEF1A2 Antibody

OAGA01882-100UL 100ul
EUR 369

EEF1A2 Rabbit Polyclonal Antibody

E10G31106 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

EEF1A2 (C-term) Rabbit pAb

E2612015 100ul
EUR 225
Description: Available in various conjugation types.

Eef1a2 ORF Vector (Rat) (pORF)

ORF066362 1.0 ug DNA
EUR 607.2

Eef1a2 ORF Vector (Mouse) (pORF)

ORF043634 1.0 ug DNA
EUR 607.2

EEF1A2 ORF Vector (Human) (pORF)

ORF003399 1.0 ug DNA
EUR 114

Eef1a2 (Myc-DDK-tagged) - Mouse eukaryotic translation elongation factor 1 alpha 2 (Eef1a2)

MR207396 10 µg Ask for price

EEF1A2 (Myc-DDK-tagged)-Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2)

RC210716 10 µg Ask for price

Human EEF1A2 knockout cell line

ABC-KH4599 1 vial Ask for price
Description: Human EEF1A2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human EEF1A2 knockdown cell line

ABC-KD4599 1 vial Ask for price
Description: Human EEF1A2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human EEF1A2 Protein Lysate 20ug

IHUEEF1A2PLLY20UG each
EUR 213
Description: Human EEF1A2 Protein Lysate 20ug

eEF1A2 binding protein Rabbit pAb

E2350160 100ul
EUR 225
Description: Available in various conjugation types.

Eef1a2 (untagged ORF) - Rat eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), (10 ug)

RN203268 10 µg Ask for price

OCOA14334-20UG - EEF1A2 Protein Lysate

OCOA14334-20UG 20ug
EUR 169

ARP90448_P050 - Eef1a2 Antibody Middle region

ARP90448_P050 100ul
EUR 389

eEF1A2 binding protein Polyclonal Antibody

ABP57282-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of eEF1A2 binding protein from Human, Mouse, Rat, Pig. This eEF1A2 binding protein antibody is for WB, IHC-P. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen recombinant protein

eEF1A2 binding protein Polyclonal Antibody

ABP57282-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of eEF1A2 binding protein from Human, Mouse, Rat, Pig. This eEF1A2 binding protein antibody is for WB, IHC-P. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen recombinant protein

eEF1A2 binding protein Polyclonal Antibody

ABP57282-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of eEF1A2 binding protein from Human, Mouse, Rat, Pig. This eEF1A2 binding protein antibody is for WB, IHC-P. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen recombinant protein

eEF1A2 binding protein Polyclonal Antibody

E20-53473 100ug
EUR 225
Description: Available in various conjugation types.

eEF1A2 binding protein Polyclonal Antibody

E44H11096 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Eef1a2 (Myc-DDK-tagged ORF) - Rat eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), (10 ug)

RR203268 10 µg Ask for price

Eef1a2 sgRNA CRISPR Lentivector set (Rat)

K6923401 3 x 1.0 ug
EUR 406.8

Lenti ORF clone of Eef1a2 (mGFP-tagged) - Mouse eukaryotic translation elongation factor 1 alpha 2 (Eef1a2)

MR207396L4 10 µg Ask for price

EEF1A2 3'UTR GFP Stable Cell Line

TU056615 1.0 ml
EUR 1672.8

Eef1a2 3'UTR GFP Stable Cell Line

TU253788 1.0 ml Ask for price

Eef1a2 3'UTR GFP Stable Cell Line

TU155610 1.0 ml Ask for price

EEF1A2 sgRNA CRISPR Lentivector set (Human)

K0655101 3 x 1.0 ug
EUR 406.8

Eef1a2 sgRNA CRISPR Lentivector set (Mouse)

K3721701 3 x 1.0 ug
EUR 406.8

AFfirm™ EEF1A2 Mouse Monoclonal Antibody

BF8103 100ul
EUR 280
Description: Human,Mouse,Rat

AFfirm™ EEF1A2 Mouse Monoclonal Antibody

BF8103-100ul 100ul
EUR 280

AFfirm™ EEF1A2 Mouse Monoclonal Antibody

BF8103-200ul 200ul
EUR 350

EEF1A2 goat polyclonal antibody, Aff - Purified

AP32067PU-N 100 µg Ask for price

EEF1A2 Protein Vector (Rat) (pPM-C-HA)

PV265448 500 ng
EUR 723.6

AAP48202-100UG - EEF1A2 Peptide - middle region

AAP48202-100UG 100ug
EUR 99

EEF1A2 Protein Vector (Rat) (pPB-C-His)

PV265446 500 ng
EUR 723.6

EEF1A2 Protein Vector (Rat) (pPB-N-His)

PV265447 500 ng
EUR 723.6

EEF1A2 Protein Vector (Rat) (pPM-C-His)

PV265449 500 ng
EUR 723.6

EEF1A2 (238-443) rabbit polyclonal antibody, Aff - Purified

AP23166PU-N 50 µl Ask for price

EEF1A2 Protein Vector (Human) (pPM-C-HA)

PV013595 500 ng
EUR 394.8

EEF1A2 Protein Vector (Mouse) (pPM-C-HA)

PV174536 500 ng
EUR 723.6

Lenti ORF clone of Eef1a2 (Myc-DDK-tagged) - Mouse eukaryotic translation elongation factor 1 alpha 2 (Eef1a2)

MR207396L3 10 µg Ask for price

ARP48202_P050-25UL - EEF1A2 Antibody - middle region

ARP48202_P050-25UL 25ul
EUR 99

ARP90448_P050-25UL - EEF1A2 Antibody - middle region

ARP90448_P050-25UL 25ul
EUR 99

OAEB03075-100UG - EEF1A2 Antibody - middle region

OAEB03075-100UG 100ug
EUR 349

EEF1A2 Protein Vector (Human) (pPB-C-His)

PV013593 500 ng
EUR 394.8

EEF1A2 Protein Vector (Human) (pPB-N-His)

PV013594 500 ng
EUR 394.8

EEF1A2 Protein Vector (Human) (pPM-C-His)

PV013596 500 ng
EUR 394.8

EEF1A2 Protein Vector (Mouse) (pPB-C-His)

PV174534 500 ng
EUR 723.6

EEF1A2 Protein Vector (Mouse) (pPB-N-His)

PV174535 500 ng
EUR 723.6

EEF1A2 Protein Vector (Mouse) (pPM-C-His)

PV174537 500 ng
EUR 723.6

Eef1a2 3'UTR Luciferase Stable Cell Line

TU203788 1.0 ml Ask for price

EEF1A2 3'UTR Luciferase Stable Cell Line

TU006615 1.0 ml
EUR 1672.8

Eef1a2 3'UTR Luciferase Stable Cell Line

TU105610 1.0 ml Ask for price

eEF1A2 binding protein Rabbit Polyclonal Antibody

E12-377 100μg/100μl
EUR 225
Description: Available in various conjugation types.

eEF1A2 binding protein Rabbit Polyclonal Antibody

E12-448 100μg/100μl
EUR 255
Description: Available in various conjugation types.

eEF1A2 binding protein Rabbit Polyclonal Antibody

EA194-100ul 100ul
EUR 124
Description: A Rabbit Polyclonal antibody against eEF1A2 binding protein from Human/ Rat/ Mouse/ Pg. This antibody is tested and validated for WB, ELISA, IHC

eEF1A2 binding protein Rabbit Polyclonal Antibody

EA194-50ul 50ul
EUR 74
Description: A Rabbit Polyclonal antibody against eEF1A2 binding protein from Human/ Rat/ Mouse/ Pg. This antibody is tested and validated for WB, ELISA, IHC

eEF1A2 binding protein Rabbit Polyclonal Antibody

EA252-100ul 100ul
EUR 124
Description: A Rabbit Polyclonal antibody against eEF1A2 binding protein from Human/ Rat/ Mouse/ Pig. This antibody is tested and validated for WB, ELISA, IHC

eEF1A2 binding protein Rabbit Polyclonal Antibody

EA252-50ul 50ul
EUR 74
Description: A Rabbit Polyclonal antibody against eEF1A2 binding protein from Human/ Rat/ Mouse/ Pig. This antibody is tested and validated for WB, ELISA, IHC

eEF1A2 binding protein Rabbit Polyclonal Antibody

ES8281-100ul 100ul
EUR 124
Description: A Rabbit Polyclonal antibody against eEF1A2 binding protein from Human/Rat/Mouse/Pig. This antibody is tested and validated for WB, ELISA, IHC

eEF1A2 binding protein Rabbit Polyclonal Antibody

ES8281-50ul 50ul
EUR 74
Description: A Rabbit Polyclonal antibody against eEF1A2 binding protein from Human/Rat/Mouse/Pig. This antibody is tested and validated for WB, ELISA, IHC

ARP48202_P050 - EEF1A2 antibody - middle region (ARP48202_P050)

ARP48202_P050 100ul
EUR 389

Eef1a2 sgRNA CRISPR Lentivector (Rat) (Target 1)

K6923402 1.0 ug DNA
EUR 184.8

Eef1a2 sgRNA CRISPR Lentivector (Rat) (Target 2)

K6923403 1.0 ug DNA
EUR 184.8

Eef1a2 sgRNA CRISPR Lentivector (Rat) (Target 3)

K6923404 1.0 ug DNA
EUR 184.8

Lenti ORF particles, Eef1a2 (GFP-tagged) - Mouse eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), 200ul, >10^7 TU/mL

MR207396L4V 200 µl Ask for price

Lenti ORF clone of Eef1a2 (mGFP-tagged ORF) - Rat eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), (10 ug)

RR203268L4 10 µg Ask for price

EEF1A2 sgRNA CRISPR Lentivector (Human) (Target 1)

K0655102 1.0 ug DNA
EUR 184.8

EEF1A2 sgRNA CRISPR Lentivector (Human) (Target 2)

K0655103 1.0 ug DNA
EUR 184.8

EEF1A2 sgRNA CRISPR Lentivector (Human) (Target 3)

K0655104 1.0 ug DNA
EUR 184.8

Eef1a2 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3721702 1.0 ug DNA
EUR 184.8

Eef1a2 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3721703 1.0 ug DNA
EUR 184.8

Eef1a2 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3721704 1.0 ug DNA
EUR 184.8

Lenti ORF particles, EEF1A2 (mGFP-tagged) - Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2), 200ul, >10^7 TU/mL

RC210716L2V 200 µl Ask for price

Lenti ORF particles, EEF1A2 (mGFP-tagged) - Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2), 200ul, >10^7 TU/mL

RC210716L4V 200 µl Ask for price

Lenti ORF particles, Eef1a2 (GFP-tagged ORF) - Rat eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), 200ul, >10^7 TU/mL

RR203268L4V 200 µl Ask for price

Lenti ORF clone of Eef1a2 (Myc-DDK-tagged ORF) - Rat eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), (10 ug)

RR203268L3 10 µg Ask for price

Lenti ORF particles, Eef1a2 (Myc-DDK-tagged) - Mouse eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), 200ul, >10^7 TU/mL

MR207396L3V 200 µl Ask for price

Lenti ORF particles, EEF1A2 (Myc-DDK tagged) - Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2), 200ul, >10^7 TU/mL

RC210716L1V 200 µl Ask for price

Lenti ORF particles, EEF1A2 (Myc-DDK tagged) - Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2), 200ul, >10^7 TU/mL

RC210716L3V 200 µl Ask for price

eEF1A2 Binding Protein Rabbit Polyclonal Antibody(1)

RA20143-100ul 100 ul
EUR 298

eEF1A2 Binding Protein Rabbit Polyclonal Antibody(1)

RA20143-50ul 50 ul
EUR 198

eEF1A2 Binding Protein Rabbit Polyclonal Antibody(GT)

RA20198-100ul 100 ul
EUR 298

eEF1A2 Binding Protein Rabbit Polyclonal Antibody(GT)

RA20198-50ul 50 ul
EUR 198

OAAB08833-400UL - EEF1A2 Antibody - C-terminal region

OAAB08833-400UL 400ul
EUR 389

AAP90448-100UG - Eef1a2 Blocking peptide (Middle region)

AAP90448-100UG 100ug
EUR 99

A number of different research investigating the advantages of ivermectin for malaria functions are ongoing/deliberate.Whereas ivermectin MDA provides promising views within the combat in opposition to malaria, we spotlight the added advantages and anticipated challenges of conducting future research in onchocerciasis-endemic areas, that are confronted with a considerable illness burden together with onchocerciasis-associated epilepsy.

Rising the frequency of ivermectin MDA in such locations could scale back the burden of each malaria and onchocerciasis, and permit for extra entomological investigations on each the Anopheles mosquitoes and the blackflies.

Upfront, acceptability and feasibility research are wanted to evaluate the endorsement by the native populations, in addition to the programmatic feasibility of implementing ivermectin MDA a number of occasions a yr.Onchocerciasis-endemic websites would doubly profit from ivermectin MDA interventions, as these will alleviate onchocerciasis-associated morbidity and mortality, whereas doubtlessly curbing malaria transmission. Involving onchocerciasis applications and different related stakeholders within the malaria/ivermectin analysis agenda would foster the implementation of pluri-annual MDA in goal communities.